An active-ingredient name and a finished medicine are different levels of description. Tesamorelin names the active substance; a branded formulation also specifies a manufactured product and its validated instructions. The distinction matters when people encounter different EGRIFTA presentations.
The EGRIFTA WR prescribing information explicitly limits its recommendations to that formulation and directs readers to the separate EGRIFTA SV information for that product. It does not tell readers to apply either set of instructions to a research vial.
Formulation is more than branding
A finished product includes the active substance, other ingredients, container and validated manufacturing process. Those features can matter to stability and delivery. Two labels mentioning tesamorelin do not, by themselves, establish that every relevant product attribute matches.
The SV and WR descriptions identify different inactive ingredient systems. SV lists mannitol, sucrose, histidine, and polysorbate 20; WR lists hydroxypropyl betadex and mannitol. The products also have their own handling requirements, which should be read in the respective official instructions. This article does not reproduce preparation or administration directions. SV description, WR description
An ingredient list is descriptive evidence. It does not, by itself, tell the reader that a copied preparation will perform like the approved one. Nor can a nominal amount on a vial serve as a complete comparison of exposure, stability, or manufacturing quality.
This is why differences in labeled amounts should not be resolved by a home conversion. The appropriate comparison is the product-specific evidence and prescribing information, not the assumption that identical milligram figures must produce identical exposure across formulations.
A research preparation introduces an additional identity and quality question. It cannot be assigned to a prescription version merely because a seller borrows the brand name in an explanation. Nor can a desired hormone response confirm which formulation it resembles.
The practical task for a patient receiving prescribed therapy is to have the pharmacist verify the actual dispensed product and its applicable instructions. If the product changes, the matching information should be checked rather than reusing remembered instructions from another presentation.
What a regulatory bridge means
The WR label describes similar systemic exposure to the earlier EGRIFTA formulation under the particular comparisons evaluated in its development program. It also explains that clinical safety evidence derives from earlier EGRIFTA trials. WR sections 6.1 and 12.3
That bridge is an evidence based connection between specified products. It is not an assertion that every formulation with the same active name will have the same exposure. Applying it to a third material would require evidence about that material, not just confidence in the original comparison.
Historical studies should therefore retain their historical intervention descriptions. Calling an older trial a WR trial would make a later product appear to have been administered before it existed in that form. Correctly distinguishing the product used from a later regulatory reliance on its results avoids this confusion.
For an editor, the same discipline applies to evidence tables: identify the formulation used in a study and avoid silently replacing it with a catalog listing. Product-specific approval is not a blanket endorsement of everything containing the active ingredient.
This article therefore provides no interchangeability claim, dose conversion or preparation instructions. The shared molecule explains why products are related; it does not establish that they are substitutes.